[{"id":"3820652a-27d6-4434-89cb-b8b33d549bab","acronym":"","url":"https://clinicaltrials.gov/study/NCT05378867","created_at":"2022-05-18T13:00:49.496Z","updated_at":"2024-07-02T16:36:10.301Z","phase":"Phase 3","brief_title":"A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC","source_id_and_acronym":"NCT05378867","lead_sponsor":"Zhejiang Teruisi Pharmaceutical Inc.","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • RAS mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • TRS003 (bevacizumab biosimilar)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 10/01/2023","primary_completion_date":" 10/01/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2022-05-18"},{"id":"0b74a3b4-04d3-473d-b5da-a3a4e74cec03","acronym":"","url":"https://clinicaltrials.gov/study/NCT04416035","created_at":"2021-01-18T21:17:03.472Z","updated_at":"2024-07-02T16:36:41.546Z","phase":"Phase 3","brief_title":"A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC","source_id_and_acronym":"NCT04416035","lead_sponsor":"Zhejiang Teruisi Pharmaceutical Inc.","biomarkers":" ALK","pipe":"","alterations":" ","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • paclitaxel • TRS003 (bevacizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 608","initiation":"Initiation: 08/17/2020","start_date":" 08/17/2020","primary_txt":" Primary completion: 10/21/2021","primary_completion_date":" 10/21/2021","study_txt":" Completion: 11/10/2021","study_completion_date":" 11/10/2021","last_update_posted":"2020-08-31"}]